Form 4: Clene Director Boosts Stake with $6.50 Stock and Warrants

Clene Inc. Director and 10% owner David J. Matlin acquired 33,333 shares of common stock and associated warrants at $6.50 per unit, signaling increased insider confidence.

Summary

• David J. Matlin, a Director and 10% owner of Clene Inc., acquired 33,333 units of the company's securities.
• Each unit was priced at $6.50 and consisted of one share of common stock, one Series A Warrant, and one Series B Warrant.
• The transaction resulted in the acquisition of 33,333 shares of common stock, 40,000 Series A Warrants, and 93,333 Series B Warrants.
• Following this transaction, Matlin beneficially owns 477,824 shares of common stock.
• The Series A Warrants have an initial exercise price of $6.00, which can increase to $7.00 based on FDA announcements for CNM-Au8 or if the common stock's volume-weighted average price (VWAP) reaches $10.00.
• The Series B Warrants also have an initial exercise price of $6.00, which can increase to $12.50 upon FDA approval of CNM-Au8 in ALS or if the common stock's VWAP reaches $25.00, or to $10.00 if the VWAP reaches $20.00.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 8

Explanation: The significant purchase by a director and 10% owner, coupled with warrants structured to benefit from positive regulatory outcomes and stock appreciation, indicates strong insider confidence in Clene Inc.'s future.

Positives

• A Director and 10% owner significantly increased their stake in Clene Inc., which typically signals strong insider confidence in the company's future prospects.
• The structured nature of the warrants, with exercise prices increasing upon positive FDA announcements and stock price appreciation, indicates management's belief in future positive catalysts and growth.

Risks

• The increased exercise prices for the Series A and Series B Warrants are contingent on specific FDA regulatory outcomes for CNM-Au8 and the company's stock performance, which are inherently uncertain.
• Failure to achieve the specified FDA milestones or stock price targets would mean the warrants are exercised at lower prices or may not be exercised at all, limiting potential upside from the warrant component.

Future Outlook

The structure of the warrants, with exercise prices increasing upon positive FDA announcements (PDUFA action date, NDA approval for CNM-Au8 in ALS) or significant stock price appreciation ($10, $20, $25 VWAP), indicates management's expectation of future positive catalysts and strong stock performance related to their drug development pipeline.

Management Comments

• The structured nature of the warrants, with exercise prices tied to significant regulatory milestones and stock performance, reflects management's confidence in the future success of CNM-Au8 and the company's growth trajectory.

Industry Context

Clene Inc. operates in the biotechnology sector, which is highly sensitive to regulatory approvals and clinical trial results, particularly from the FDA. Insider purchases, especially by a significant owner and director, are often interpreted as a strong positive signal in this high-risk, high-reward industry, suggesting confidence in upcoming catalysts or the long-term value of the company's drug candidates like CNM-Au8.

Comparison to Industry Standards

• Insider buying is a common occurrence across industries, and in the biotechnology sector, it is often viewed as a strong signal of confidence, especially when tied to specific drug development milestones.
• The structure of these warrants, with escalating exercise prices based on FDA approvals and stock performance, is a standard mechanism used in biotech to align insider incentives with shareholder value creation, similar to practices seen in companies like Biogen or Sarepta Therapeutics during key drug approval phases.

Related Party Transactions

• The transaction involves a director and 10% owner, David J. Matlin, purchasing securities directly from Clene Inc. via a Securities Purchase Agreement dated January 8, 2026.

Stakeholder Impact

• Shareholders: Potential positive signal of confidence from a significant insider, which could positively influence market perception. There is also potential for future dilution if warrants are exercised.
• Company: Receives capital from the sale of units, strengthening its financial position.

Next Steps

• Public announcement of the U.S. FDA's PDUFA action date for the new drug application (NDA) for CNM-Au8.
• Public announcement of FDA's written approval of the NDA for CNM-Au8 in ALS.
• Monitoring the volume-weighted average price (VWAP) of the company's common stock for potential warrant exercise price triggers.

Key Dates

Recommendation

The significant purchase of common stock and warrants by a director and 10% owner, David J. Matlin, signals strong insider confidence in Clene Inc.'s future prospects. The warrant structure, with increasing exercise prices tied to key FDA milestones for CNM-Au8 in ALS and stock price appreciation, suggests a belief in substantial upside potential. This insider activity, combined with the company's progress towards regulatory approvals, presents a compelling 'buy' signal for investors looking for growth in the biotechnology sector.

Keywords

Clene Inc., CLNN, Insider Trading, Form 4, Director Purchase, Warrants, Biotechnology, FDA Approval, CNM-Au8, ALS, Equity Purchase